Investing.com UK - Financial Markets Worldwide
Get 40% Off
Get 40% Off
💰 Warren Buffett reveals a $6.72 billion stake in ChubbCopy Portfolios

Why Are Albireo Pharma Shares Gaining Today?

Published 11/10/2022, 14:37
Updated 11/10/2022, 15:10
© Reuters. Why Are Albireo Pharma Shares Gaining Today?
ALBO
-

  • Albireo Pharma Inc (NASDAQ: ALBO) announced topline results from the Phase 3 ASSERT study evaluating the safety and efficacy of Bylvay in Alagille syndrome (ALGS) patients from birth to early adulthood.
  • The trial met its primary endpoint of improvement in pruritus and its key secondary endpoint of reduction in serum bile acids.
  • Statistically significant improvements in multiple sleep parameters were observed as early as week 1-4 compared to patients on placebo, with continued improvement through week 24.
  • Bylvay (odevixibat) is the first drug approved in the U.S. for pruritus in patients three months and older in all progressive familial intrahepatic cholestasis.
  • There were no patient discontinuations, and Bylvay was well tolerated, with low rates of drug-related diarrhea (11.4% vs. 5.9% placebo).
  • The company continues to enroll patients in the Phase 3 BOLD study in biliary atresia. Enrollment is expected to conclude by the end of this year. Topline data is planned for 2024.
  • Albireo has engaged in discussions with the FDA and European Medicines Agency about the Phase 3 study design. Both have indicated that a successful single study would be sufficient for approval. The company plans to submit regulatory filings in the U.S. and EU immediately.
  • Price Action: ALBO shares are up 7.96% at $22.10 on the last check Tuesday.

Read the original article on Benzinga

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.